Chronic Lymphocytic Leukemia Clinical Trials in Portland, Oregon
8 studies are recruiting for chronic lymphocytic leukemia in Portland, Oregon right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.
Search these by distance from you
Studies now recruiting
-
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma. Venetoclax is in a class of medications called B-cell lymph…
- Stage
- Phase 3
- Ages
- 18 and older
- Site
- Providence Portland Medical Center, Portland, Oregon
- Locations
- 632 in total
- Run by
- National Cancer Institute (NCI)
-
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in the laboratory may help researchers develop tests for the earl…
- Stage
- Not phased
- Ages
- 40 to 75
- Site
- Providence Portland Medical Center, Portland, Oregon
- Locations
- 745 in total
- Run by
- Alliance for Clinical Trials in Oncology
-
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
This phase III trial compares the effect of adding sonrotoclax to zanubrutinib versus zanubrutinib alone for the treatment of patients with untreated chronic lymphoblastic leukemia (CLL)/small lymphocytic lymphoma (SLL). Sonrotoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhi…
- Stage
- Phase 3
- Ages
- 65 and older
- Site
- Providence Portland Medical Center, Portland, Oregon
- Locations
- 210 in total
- Run by
- Alliance for Clinical Trials in Oncology
-
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
This is a Phase 1/2, first-in-human, open-label, dose-escalating trial designed to assess the safety and efficacy of VNX-101 in patients with relapsed or refractory CD19-positive hematologic malignancies.
- Stage
- Phase 1
- Ages
- 13 to 90
- Site
- Oregon Health & Science University, Portland, Oregon
- Locations
- 11 in total
- Run by
- Vironexis Biotherapeutics Inc.
-
A Long-term Extension Study of PCI-32765 (Ibrutinib)
The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been completed according to the parent protocol, are actively rece…
- Stage
- Phase 3
- Ages
- 18 and older
- Site
- Kaiser Permanente, Portland, Oregon
- Locations
- 175 in total
- Run by
- Janssen Research & Development, LLC
-
Study of SGR-1505 in Mature B-Cell Neoplasms
The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or recommended dose (RD) of SGR-1505.
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- Oregon Health and Science University - Knight Cancer Institute, Portland, Oregon
- Locations
- 36 in total
- Run by
- Schrödinger, Inc.
-
Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
This phase Ib trial tests the safety and effectiveness of tafasitamab, acalabrutinib, and obinutuzumab in treating patients with previously untreated chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). CLL and SLL are types of cancer that develops from a specific white blood ce…
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- OHSU Knight Cancer Institute, Portland, Oregon
- Run by
- OHSU Knight Cancer Institute
-
Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
This study evaluates immune responses after CAR-T therapy to find out if CAR-T therapy reduces the effectiveness of the vaccines (vaccine immunity) against diseases such as measles, mumps and rubella, among others in patients with multiple myeloma and non-Hodgkin lymphoma.
- Stage
- Not phased
- Ages
- 18 and older
- Site
- OHSU Knight Cancer Institute, Portland, Oregon
- Run by
- OHSU Knight Cancer Institute
How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.
What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.
Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.